semaglutide ckd approval Ozempic picks up FDA indication to treat chronic kidney disease Semaglutides Are Poised to Remake
Description
Do not use the product after the expiry date printed on the label
Science 271 , 994996 (2016)
Basilea originally partnered with Johnson & Johnson to develop the molecule in 2005 but ran into a series of regulatory challenges
SURMOUNT-1 demonstrated average body weight reductions of 15% at the 5mg dose, 19.5% at 10mg, and 20.9% at 15mg over 72 weeks, compared to 3.1% with placebo
